Acadia's Alzheimer’s Drug Voted Down by FDA Advisory Committee

The U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted against Acadia Pharmaceutical’s supplemental New Drug Application (sDNA) of Nuplazid (pimavanserin) tablets for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis by a vote of 9-3.